| Symbol | ACOG |
|---|---|
| Name | ALPHA COGNITION INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 1200-750 W PENDER ST, VANCOUVER, British Columbia, V6C 2T8, Canada |
| Telephone | (858) 344-4375 |
| Fax | — |
| — | |
| Website | https://www.alphacognition.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001655923 |
| Description | Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases. On July 26, 2024, the Company received FDA approval for the Companys New Drug Application (the NDA) for ZUNVEYL® (benzgalantamine) oral tablet for the treatment of mild-to-moderate Alzheimers disease. The Companys focus is on the development of commercial manufacturing and sales of ZUNVEYL. The Company has three additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimers disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (ALPHA-1062IN) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion) and Progranulin GEMs, for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis. Additional info from NASDAQ: |
Opaleye Management Inc. 🟢 acquired 152.5K shares of Alpha Cognition Inc. (ACOG) at $6.50 Transaction Date: Jun 25, 2026 | Filing ID: 031063
Read moreNew Form SCHEDULE 13G/A - Alpha Cognition Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001493152-26-031066 <b>Size:</b> 23 KB
Read more(99% Neutral) ALPHA COGNITION INC. (ACOG) Announces New Board Appointment
Read moreAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Read moreAlpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
Read moreOpaleye Management Inc. 🟢 acquired 7.7K shares of Alpha Cognition Inc. (ACOG) at $5.99 Transaction Date: Jun 11, 2026 | Filing ID: 028783
Read moreOpaleye Management Inc. 🟢 acquired 10.1K shares of Alpha Cognition Inc. (ACOG) at $5.83 Transaction Date: Jun 05, 2026 | Filing ID: 027927
Read moreAlpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
Read moreOpaleye Management Inc. 🟢 acquired 73.7K shares of Alpha Cognition Inc. (ACOG) at $5.90 Transaction Date: May 27, 2026 | Filing ID: 026472
Read moreOpaleye Management Inc. 🟢 acquired 24.4K shares of Alpha Cognition Inc. (ACOG) at $5.89 Transaction Date: May 20, 2026 | Filing ID: 025011
Read more